Cetuximab-based therapy in elderly comorbid patients with metastatic colorectal cancer
| Autor: | Diana Lüftner, L. Böning, H. Kröning, Kurt Possinger, Christian Jehn |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Adult
Male Oncology Cancer Research medicine.medical_specialty Adolescent Colorectal cancer Cetuximab Antineoplastic Agents macromolecular substances Antibodies Monoclonal Humanized chemotherapy elderly patients Young Adult Internal medicine medicine Humans Neoplasm Metastasis Young adult Aged Aged 80 and over Performance status business.industry metastatic colorectal cancer Antibodies Monoclonal Middle Aged medicine.disease Rash Surgery Clinical trial Irinotecan Exact test Clinical Study Female medicine.symptom Colorectal Neoplasms business medicine.drug |
| Zdroj: | British Journal of Cancer |
| ISSN: | 1532-1827 0007-0920 |
| DOI: | 10.1038/bjc.2011.554 |
| Popis: | Background: Clinical trials under-represent patients (pts) >65 years. Non-interventional studies (NISs) help to evaluate therapies in daily practice. This NIS evaluates efficacy and safety of cetuximab in combination with chemotherapy in metastatic colorectal cancer (mCRC) pts aged >65 years vs ⩽65 years. Methods: A total of 657 pts were recruited into the NIS and analysed applying descriptive statistics and χ2 or Fisher's exact test. Results: A total of 309 and 305 pts aged ⩽65 and >65 years, respectively, were documented; 80% showing a reduced ECOG status of 1–2 and 95% having received at least one palliative treatment. Cetuximab was combined with irinotecan according to approval status. Grade III/IV toxicities occurred in 20% of pts without any difference between age groups although the older pts had significantly more pre-existing comorbidities (P=0.001). A total of 64.2% of the pts developed skin rash, which was strongly related to response (P65 years. Progression-free survival (PFS) did not differ between pts 18–65 years old (6.5 months) in comparison with pts >65 years (7.0 months). In a multivariate analysis only ECOG status had a negative impact on PFS (HR: 0,675; 95% Cl, 0.53–0.87; P=0.0019). Conclusion: This NIS reports one of the largest mCRC collectives >65 years and reduced performance status. Cetuximab has a similar efficacy and safety profile for pts aged ⩽65 and >65 years. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|